Advisory: Give yourself extra time when travelling by car to Toronto General Hospital, Princess Margaret Cancer Centre, or Toronto Rehab University Centre. City of Toronto construction on University Ave. may cause delays.
At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
Toronto (Oct. 4, 2018) – Scientists at the Krembil Research Institute have developed a novel therapeutic treatment that has the potential to stop knee and spine osteoarthritis in its tracks.
A team led by Principal Investigator Dr. Mohit Kapoor, Arthritis Research Director at UHN, published the results today in Annals of the Rheumatic Diseases in a paper titled "microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints."
"This is important because there are currently no drugs or treatments available to patients that can stop osteoarthritis," says Dr. Kapoor, a Krembil Senior Scientist.
Osteoarthritis is the most common form of arthritis. It affects about five million Canadians and is characterized by a breakdown of the protective cartilage found in the body's spine, hand, knee and hip joints.
"Current treatments for osteoarthritis address the symptoms, such as pain, but are unable to stop the progression of the disease," says Dr. Kapoor. "The blocker we've tested is disease modifying. It has the ability to prevent further joint destruction in both knee and spine."
Utilizing a variety of experimental models, including animal models and human tissue samples, the Krembil team zeroed in on a biomarker, or molecule, called microRNA-181a-5p, which is believed to also cause the inflammation, cartilage destruction and collagen depletion.
Using a blocker consisting of Locked Nucleic Acid-Antisense Oligonucleotides (LNA-ASO), the team was able to stop destruction and protect the cartilage.
"The blocker is based on antisense technology. When you inject this blocker into the joints, it blocks the destructive activity caused by microRNA-181-5p and stops cartilage degeneration," said Dr. Akihiro Nakamura, first author of the paper and a post-doctoral research fellow in the Kapoor Lab.
In addition to testing with animal models, the research team applied this approach using cells and tissues from Toronto Western Hospital patients who have knee and/or spine osteoarthritis.
"The technology in osteoarthritis is in its infancy, but the research has now taken a big step forward. If we are able to develop a safe and effective injection for patients, this discovery could be a game changer," said Dr. Raja Rampersaud, an orthopedic spine surgeon and clinician scientist at Toronto Western who collaborated with the Kapoor team.
Next steps for the research team include commencement of safety studies, determining proper dosage and developing a method for injecting the blocker directly into the knee and spine joints.
Funding for this study was provided by the Krembil Foundation, The Toronto General & Western Hospital Foundation and The Canadian Institutes of Health Research (CIHR).
The Krembil Research Institute (or "Krembil") is one of the principal research institutes of the University Health Network. The Krembil is focussed on research programs dedicated to brain & spine, arthritis and vision disorders with a goal to alleviate debilitating chronic disease through basic, translational and clinical research. Krembil is located at the Toronto Western Hospital in downtown Toronto. For more information, visit Krembil Research Institute.
University Health Network consists of Toronto General and Toronto Western Hospitals, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, and The Michener Institute of Education at UHN. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. University Health Network is a research hospital affiliated with the University of Toronto.
Phone: 416 340 4636